Form 4: Akero Therapeutics COO Jonathan Young Reports Future Share Acquisition via ESPP

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported a pre-planned acquisition of 890 shares of common stock at $23.868 per share, scheduled for June 30, 2025, through the company's Employee Stock Purchase Plan.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported an acquisition of common stock.
• The transaction, which is scheduled for June 30, 2025, was made pursuant to a Rule 10b5-1(c) plan.
• Young acquired 890 shares of Akero Therapeutics common stock.
• The shares were purchased at a price of $23.868 per share.
• This acquisition was made pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price represents 85% of the closing price of the Issuer's common stock on January 2, 2025.
• The transaction is exempt under Rule 16b-3(c) and Rule 16b-3(d).
• Following this transaction, Jonathan Young directly beneficially owns 197,484 shares of common stock.
• Additionally, 60,000 shares are held indirectly in three irrevocable trusts (20,000 shares each) for the benefit of his children, with his spouse as trustee, though Young disclaims beneficial ownership of these trust shares.

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Operating Officer, even through an ESPP and a Rule 10b5-1 plan, generally signals management confidence in the company's future. While the amount is relatively small in the context of total holdings, it's a positive indicator of alignment with shareholder interests.

Positives

• Chief Operating Officer Jonathan Young is acquiring additional shares in the company through a pre-planned transaction, indicating confidence in the company's future.
• The acquisition is made through an Employee Stock Purchase Plan (ESPP), which typically allows employees to purchase shares at a discount, representing a benefit to the employee and aligning interests.
• The transaction is part of a Rule 10b5-1(c) plan, demonstrating a pre-arranged, transparent approach to insider trading.

Negatives

• No specific negative aspects are detailed in this Form 4 filing.

Risks

• No specific risks related to the company's operations or financial health are detailed in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance regarding the company's business operations or financial performance are provided in this Form 4 filing, which primarily reports an insider transaction.

Management Comments

• No direct management comments or notable quotes are provided beyond the details of the transaction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing reports an individual insider transaction and does not provide data for comparison to industry standards or benchmarks.

Related Party Transactions

• Shares are held indirectly in three irrevocable trusts for the benefit of the Reporting Person's children, with the Reporting Person's spouse as trustee. The Reporting Person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: The acquisition of shares by a key executive may be viewed positively as it aligns management's interests with those of shareholders.
• Employees: The transaction highlights the existence and utilization of an Employee Stock Purchase Plan (ESPP), which is a benefit for eligible employees.

Next Steps

• No specific future actions or milestones for the company are detailed in this Form 4 filing.

Key Dates

Keywords

Akero Therapeutics, AKRO, Jonathan Young, Chief Operating Officer, Insider Trading, Form 4, SEC Filing, Employee Stock Purchase Plan, ESPP, Stock Acquisition, Beneficial Ownership, Rule 10b5-1